Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI scans and blood tests could predict who responds to stomach cancer chemotherapy

NCT ID NCT07697079

Knowledge-focused Sponsor: Liu Yang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study is testing whether artificial intelligence can predict how well stomach cancer patients will respond to chemotherapy given before surgery. Researchers will collect CT scans, ultrasound images, and blood samples from 300 patients with locally advanced gastric cancer. Using deep learning, they aim to build a model that identifies good versus poor responders, potentially allowing doctors to personalize treatment plans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a non-invasive way to predict which patients will benefit from chemotherapy, helping tailor treatment and avoid unnecessary side effects.
What could go wrong
This is an early-stage observational study, not a treatment trial. The AI model may not be accurate enough for clinical use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2027

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with histologically confirmed GC at a locally advanced stage (cT2-4N0/+M0) who received NACT

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Capable of understanding the study and voluntarily signing the written informed consent form (ICF) prior to any study-specified research procedures. 2. Aged ≥18 and ≤80 years old at the time of ICF signing. 3. Pathologically confirmed locally advanced gastric cancer (LAGC, cT2NxM0-cT4NxM0) with clinical indications for neoadjuvant chemotherapy. 4. Completion of gastrointestinal contrast-enhanced ultrasound and contrast-enhanced abdominal CT before neoadjuvant chemotherapy. 5. Provision of peripheral blood samples before chemotherapy (for genetic and protein detection). 6. Availability of postoperative pathological specimens for TRG grading after standardized neoadjuvant chemotherapy. 7. Willing and able to comply with all study protocol requirements. Exclusion Criteria: 1. Diagnosis of non-primary gastric cancer. 2. Incomplete imaging data, failure to collect peripheral blood samples, or substandard sample quality. 3. Discontinued chemotherapy, modified treatment regimen, or lack of complete postoperative pathological assessment. 4. Unavailable follow-up data precluding evaluation of chemotherapy response. 5. Concurrent participation in another clinical trial; or any other conditions judged by investigators to warrant subject withdrawal, including severe comorbidities requiring simultaneous treatment (psychiatric disorders included), alcohol dependence, substance abuse, or familial/social factors that may compromise subject safety or treatment compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • QianfoshanH

    Jinan, Shandong, 250014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.